213 related articles for article (PubMed ID: 28470686)
1. Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer.
Sideras K; Biermann K; Yap K; Mancham S; Boor PPC; Hansen BE; Stoop HJA; Peppelenbosch MP; van Eijck CH; Sleijfer S; Kwekkeboom J; Bruno MJ
Int J Cancer; 2017 Aug; 141(3):572-582. PubMed ID: 28470686
[TBL] [Abstract][Full Text] [Related]
2. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
5. PD-L1, Galectin-9 and CD8
Sideras K; Biermann K; Verheij J; Takkenberg BR; Mancham S; Hansen BE; Schutz HM; de Man RA; Sprengers D; Buschow SI; Verseput MC; Boor PP; Pan Q; van Gulik TM; Terkivatan T; Ijzermans JN; Beuers UH; Sleijfer S; Bruno MJ; Kwekkeboom J
Oncoimmunology; 2017; 6(2):e1273309. PubMed ID: 28344887
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
[TBL] [Abstract][Full Text] [Related]
8. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
[TBL] [Abstract][Full Text] [Related]
9. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
[TBL] [Abstract][Full Text] [Related]
11. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
[TBL] [Abstract][Full Text] [Related]
12. Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance.
Fong D; Steurer M; Obrist P; Barbieri V; Margreiter R; Amberger A; Laimer K; Gastl G; Tzankov A; Spizzo G
J Clin Pathol; 2008 Jan; 61(1):31-5. PubMed ID: 16775119
[TBL] [Abstract][Full Text] [Related]
13. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
[TBL] [Abstract][Full Text] [Related]
14. Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands.
Mosconi C; de Arruda JAA; de Farias ACR; Oliveira GAQ; de Paula HM; Fonseca FP; Mesquita RA; Silva TA; Mendonça EF; Batista AC
Oral Oncol; 2019 Jan; 88():95-101. PubMed ID: 30616805
[TBL] [Abstract][Full Text] [Related]
15. Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
Patil PA; Blakely AM; Lombardo KA; Machan JT; Miner TJ; Wang LJ; Marwaha AS; Matoso A
Histopathology; 2018 Jul; 73(1):124-136. PubMed ID: 29489025
[TBL] [Abstract][Full Text] [Related]
16. Role of immune microenvironment in gastrointestinal stromal tumours.
Blakely AM; Matoso A; Patil PA; Taliano R; Machan JT; Miner TJ; Lombardo KA; Resnick MB; Wang LJ
Histopathology; 2018 Feb; 72(3):405-413. PubMed ID: 28871595
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
18. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
Mills AM; Peres LC; Meiss A; Ring KL; Modesitt SC; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Wallace K; Schildkraut JM
Int J Gynecol Pathol; 2019 Mar; 38(2):157-170. PubMed ID: 29485423
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
Kim KH; Choi KU; Kim A; Lee SJ; Lee JH; Suh DS; Kwon BS; Hwang C
J Ovarian Res; 2019 Jun; 12(1):56. PubMed ID: 31208449
[TBL] [Abstract][Full Text] [Related]
20. Expression and Clinical Significance of Herpes Virus Entry Mediator (HVEM) in Breast Cancer.
Tsang JYS; Chan KW; Ni YB; Hlaing T; Hu J; Chan SK; Cheung SY; Tse GM
Ann Surg Oncol; 2017 Dec; 24(13):4042-4050. PubMed ID: 28612127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]